Monoamine oxidase inhibitors pharmacokinetics

Mallinger, A.G., and Smith, E. (1991). Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmacol Bull 27 493-502. 

Some of the triptans are metabolized by monoamine oxidase and they should not be used with monoamine oxidase inhibitors. This includes almotriptan (34), rizatriptan (35), sumatriptan (36), and zolmitriptan (28). The effect of moclobemide on the pharmacokinetics of almotriptan was less than with other triptans (34). 

Lower respiratory tract infections treatment of Macrolide antibiotics Manic symptoms drug-induced Migraine headaches treatment of Monoamine oxidase inhibitors contemporary treatment of depression Multiple sclerosis treatment of Myasthenia gravis treatment of Mycoses treatment of deep-seated organisms Myoclonus treatment of Narcolepsy treatment of Neurotransmitters and their receptor subtypes Newborns undeveloped pharmacokinetic profile Nitrate products... 

A. Classification and Pharmacokinetics The major classes of antidepressant drugs are shown in Figure 30-1 tricyclic antidepressants, heterocyclic antidepressants, selective serotonin reuptake inhibitors, and monoamine oxidase inhibitors. 

SSRIs), in the past 20 years has significantly affected the treatment of depression. The SSRIs have become first-line therapy in the treatment of major depressive disorder, and they also are used as adjunct treatment in other mood disorders. This new generation of antidepressants has more favorable side effect and pharmacokinetic profiles than the older generations of antidepressants, such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). This has resulted in improved patient compliance and therapeutic outcomes for patients with major depressive disorder. 

Table 21.15. Pharmacokinetics of the Monoamine Oxidase Inhibitors (MAOIs) Phenelzine Tranylcypromine Parameters (Nardil) (Parnate) Meclobemide ...

Tranylcypromine is a chiral monoamine oxidase inhibitor used in the treatment of depression. The drug is similar to mefloquine in that it is contains a diastereomeric structure but is only administered as the 50 50 combination of the (- -)-lS,2R and (—)-lR,2S species. The enantiomers possess differences in their pharmacological properties in that (-I-) tranylcypromine is much more effective than its antipode in MAO inhibition, but the (—) enantiomer causes greater diminution of catecholamine reuptake and release than (-I-) enantiomer [147]. With respect to its pharmacokinetics (Table 1), the (-I-) enantiomer seemed to be cleared via the oral route 4 to 8 times more rapidly than antipode based on significantly... 

Glaxo Pharmaceuticals UK Limited. A study to determine whedier the pharmacokinetics, safety or tolerability of subcutaneously administered sumatriptan (6 mg) are altered by interaction with concurrent oral monoamine oxidase inhibitors. Data on file (Protocol C92-050),... 

Dingemanse J,KneerJ, WaUnofer A, KettlerR,ZurcherG, Koulu M, Korn A. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors moclobemide and selegiline. Clin Neuropharmacol (1996) 19, 399-414. 

Fox AW. Subcutaneous sumatriptan pharmacokinetics delimiting the monoamine oxidase inhibitor effect. Headache 2010 50 (2) 249-55. 

Desmethylselegiline is also an irreversible inhibitor of monoamine oxidase B in humans. There is evidence that the 1-stereoisomers of 1-amphetamine and 1-methamphetamine may have some qualitatively different actions from their d-isomer counterparts, which might result in beneficial clinical effects and could complement any beneficial clinical actions of selegiline itself. Food has no effect on the pharmacokinetics of desmethylselegiline, methamphetamine, and amphetamine. At a dose of 10 mg per day, selegiline is devoid of the cheese effect that is, it does not cause hypertension when taken with tyramine-containing foods such as cheese. 

Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet 1995 29 292-332. 

Takasaki, W. Yamamura, M. Shigehara, E. Suzuki, Y. Tonohiro, T. Hara, T. Tanaka, Y. Stereoselective pharmacokinetics of RS-8359, a selective and reversible inhibitor of A-t5 pe monoamine oxidase, in rats, mice, dogs, and monkeys. Biol. Pharm. Bull. 1999, 22, 498 503. 

---